The Oversight and Reform Committee of the House of Representatives has scheduled a hearing this week to reveal findings in the panel’s three-year investigation into pharmaceutical pricing and business practices. The hearing will also look at the need for structural reforms for the industry.
We will report in future updates any significant findings that may be revealed by the study.
